BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-kpti-xport-ec-042-mid-2026-endometrial-readout@catalyst-calendar.local
DTSTAMP:20260720T200642Z
DTSTART:20260715T120000Z
DTEND:20260715T123000Z
SUMMARY:Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据读出窗口
DESCRIPTION:Karyopharm披露XPORT-EC-042三期研究已完成入组，预计2026年中披露selinexor维持治疗TP53野生型晚期或复发子宫内膜癌顶线数据；若阳性将影响妇科肿瘤维持治疗格局。\\nImpact score: 67\\nExpected: 读出结果将影响selinexor跨癌种拓展、子宫内膜癌维持治疗和XPO1抑制剂平台估值。\\nAffected: KPTI(subject\, unknown\, score 84)\; MRK(peer\, mixed\, score 48)\; GSK(peer\, mixed\, score 46)\; XBI(etf\, mixed\, score 42)\\nSources: Karyopharm Q1 2026 update: https://investors.karyopharm.com/2026-05-14-Karyopharm-Reports-First-Quarter-2026-Financial-Results-and-Completion-of-Phase-3-Endometrial-Cancer-Trial-Enrollment\\nKaryopharm FY2025 results: https://investors.karyopharm.com/2026-02-12-Karyopharm-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Company-Progress\\nClinicalTrials.gov XPORT-EC-042: https://clinicaltrials.gov/study/NCT05611931\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-kpti-xport-ec-042-mid-2026-endometrial-readout
CATEGORIES:guidance\,US\,clinical readout\,Phase 3\,endometrial cancer\,selinexor
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据读出窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据读出窗口
END:VALARM
END:VEVENT
END:VCALENDAR